Pancuronium Bromide – This medication is a muscle relaxant, prescribed as an adjunct to general anesthesia for induction of skeletal muscle relaxation. It is also used for facilitation of management of patients undergoing mechanical ventilation (breathing management); facilitation of tracheal intubation.
Pancuronium dibromide is a competitive nicotinic acetylcholine receptor antagonist, used as a muscle relaxant.
Pancuronium results in open channel block of embryonic-type nicotinic acetylcholine receptor channels after coapplication of blocker and acetylcholine, characterized by decrease of the time constant of current decay. Pancuronium also results in competitive block of embryonic-type nicotinic acetylcholine receptor channels. Pancuronium increases heart rate, vecuronium and rocuronium produces positive inotropic effects, and vecuronium shortens refractoriness in isolated rat atria. Pancuronium (0.5 mM) induces a complete fade of the tetanic contraction while leaving the twitch unaffected in the extensor digitorum longus muscle of the rat. Pancuronium decreases the amplitude and increases the tetanic rundown of trains of endplate potentials (e.p.ps) evoked in the frequency of 50 Hz in the extensor digitorum longus muscle of the rat.
Pancuronium decreases tidal volume (VT) and minute ventilation (VE) in high dose dogs by 82%. Pancuronium decreases tidal volume (VT) and minute ventilation (VE) in low dose dogs by 40% and 55%. Pancuronium limits cerebral hyperemia during prolonged seizures by attenuating increases in blood pressure as a result of elimination of skeletal muscle activity in newborn pigs. Pancuronium results in a significant difference with control is observed at gallamine concentrations ranging from 0.032-0.32 mM in tracheal smooth muscle strips from guinea-pigs.